{"id":"NCT00384397","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers","officialTitle":"An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-08","completion":"2009-02","firstPosted":"2006-10-06","resultsPosted":"2011-06-02","lastUpdate":"2016-04-14"},"enrollment":1128,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Meningitis","Measles","Mumps","Rubella","Varicella"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","otherNames":["Menactra®","ProQuad®"]},{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","otherNames":["Menactra®","Prevnar®"]}],"arms":[{"label":"Group 1: Menactra® Vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Menactra® + MMRV","type":"EXPERIMENTAL"},{"label":"Group 3: Menactra® + PCV","type":"EXPERIMENTAL"}],"summary":"This is a Phase III, modified single-blind, randomized, parallel-group, multicenter, comparative trial in the United States designed to evaluate the immunogenicity and safety of two doses of Menactra vaccine administered alone, and concomitantly with other routine pediatric vaccines typically administered between 12 and 15 months of age.\n\nPrimary Objective:\n\nTo evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135.\n\nSecondary Objectives:\n\nImmunogenicity\n\n* To evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135, when Menactra vaccine is administered alone or concomitantly with Hib and MMRV vaccines.\n* To evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135, when Menactra vaccine is administered alone or concomitantly with PCV vaccine.\n\nSafety\n\n\\- To describe the safety profile within 7 and 30 days of each vaccination, and serious adverse events (SAEs) throughout the course of the study.","primaryOutcome":{"measure":"Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)","timeFrame":"30 days post-visit 2 Menactra®","effectByArm":[{"arm":"Group 1: Menactra® Vaccine","deltaMin":96,"sd":null},{"arm":"Group 2: Menactra® + MMRV","deltaMin":93,"sd":null},{"arm":"Group 3: Menactra® + PCV","deltaMin":91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"249 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":407},"commonTop":["Otitis media","Upper respiratory tract infection","Teething","Diarrhoea","Pyrexia"]}}